The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
BOSTON and SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the“Company”), a clinical-stage biotechnology company dedicated to the discovery and ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Rapport Therapeutics, Inc. (NASDAQ:RAPP) stock traded higher on Monday, with a session volume of 3.20 million compared to the average volume of 179.3 thousand, according to data from Benzinga Pro. On ...
(RTTNews) - Rapport Therapeutics (RAPP) announced that the Phase 2a clinical trial of RAP-219 in patients with drug-resistant focal onset seizures met its primary endpoint, demonstrating a ...
(MENAFN- GlobeNewsWire - Nasdaq) New analysis examines RAP-219's effect during the first month of treatment and consistency of efficacy over the treatment period, effectiveness across baseline disease ...
Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well tolerated Patients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results